Key result
Novel myostatin antibody GYM329 enhances muscle mass and strength in animal models.
Why the study?
Myostatin is an attractive target for muscle disease therapy, leading to the development of an antibody therapeutic approach to maximize the potential of myostatin-targeted therapy.
Does the novel latent myostatin-specific sweeping antibody GYM329 improve muscle mass and strength in preclinical models of muscle disease?
Does the novel latent myostatin-specific sweeping antibody GYM329 improve muscle mass and strength in preclinical models of muscle disease?
A novel sweeping antibody targeting latent myostatin (GYM329) demonstrates superior muscle strength enhancement compared to conventional anti-myostatin agents in preclinical models.
Should not yet change practice; hypothesis-generating for myostatin inhibition in human muscle disease.
Myostatin, a member of the transforming growth factor-b superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach that maximizes the potential of myostatin-targeted therapy. We generated an antibody, GYM329, that specifically binds the latent form of myostatin and inhibits its activation. Additionally, via “sweeping antibody technology”, GYM329 reduces or “sweeps” myostatin in the muscle and plasma. Compared with conventional anti-myostatin agents, GYM329 and its surrogate antibody exhibit superior muscle strength-improvement effects in three different mouse disease models. We also demonstrate that the superior efficacy of GYM329 is due to its myostatin specificity and sweeping capability. Furthermore, we show that a GYM329 surrogate increases muscle mass in normal cynomolgus monkeys without any obvious toxicity. Our findings indicate the potential of GYM329 to improve muscle strength in patients with muscular disorders.
No takes yet. Share an insight, caveat, or question.
Muramatsu et al. (2020) studied Muscle disease. GYM329 (and surrogates GYM-mFc, GYM-cyFc) vs. Vehicle, landogrozumab, domagrozumab, bimagrumab was evaluated on Muscle mass and grip strength. GYM329, a novel myostatin-specific sweeping antibody, significantly enhanced muscle strength and increased muscle mass in mouse models of muscle disease and cynomolgus monkeys.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: